Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model

References

• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Mar 22;12(4):278–13. doi:10.1038/nrc3236.
   PubMed Web of Science ®Google Scholar
• Hajdu SI, Vadmal M. A note from history: landmarks in history of cancer, part 6. Cancer. 2013 Dec 1;119(23):4058–82.
   PubMed Web of Science ®Google Scholar
• Wold ED, Smider VV, Felding BH. Antibody therapeutics in oncology. Immunotherapy (Los Angeles). 2016 Mar;2(1). doi:10.4172/2471-9552.1000108
   Google Scholar
• Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019 Aug 31;394(10200):793–804. doi:10.1016/S0140-6736(19)31774-X.
   PubMed Web of Science ®Google Scholar
• Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019 Jun 1;111(6):538–49. doi:10.1093/jnci/djz035.
   PubMedGoogle Scholar
• Anagnostis P, Efstathiadou ZA, Polyzos SA, Adamidou F, Slavakis A, Sapranidis M, Litsas ID, Katergari S, Selalmatzidou D, Kita M. Acromegaly: presentation, morbidity and treatment outcomes at a single centre. Int J Clin Pract. 2011 Aug;65(8):896–902. doi:10.1111/j.1742-1241.2011.02682.x.
   PubMed Web of Science ®Google Scholar
• Roy B, Bhattacharjee A, Xu B, Ford D, Maizel AL, Cathcart MK. IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of stats. J Leukoc Biol. 2002 Sep;72(3):580–89.
   PubMed Web of Science ®Google Scholar
• Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med. 2000 May;6(5):440–49. doi:10.1007/BF03401786.
   PubMed Web of Science ®Google Scholar
• Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. Structure. 2010 Mar 10;18(3):332–42. doi:10.1016/j.str.2010.01.003.
   PubMed Web of Science ®Google Scholar
• Tabata Y, Khurana Hershey GK. IL-13 receptor isoforms: breaking through the complexity. Curr Allergy Asthma Rep. 2007 Sep;7(5):338–45. doi:10.1007/s11882-007-0051-x.
   PubMed Web of Science ®Google Scholar
• McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015 Sep;75(1):38–50. doi:10.1016/j.cyto.2015.05.023.
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006 Jan;12(1):99–106. doi:10.1038/nm1332.
   PubMed Web of Science ®Google Scholar
• He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, Ahangari F, Ma B, Herzog EL, Rosenberg SA, Li Y et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor alpha2. Cell Rep. 2013 Aug 29;4(4):830–41. doi:10.1016/j.celrep.2013.07.032.
   PubMed Web of Science ®Google Scholar
• Lee CM, He CH, Nour AM, Zhou Y, Ma B, Park JW, Kim KH, Dela Cruz C, Sharma L, Nasr ML, et al. IL-13Ralpha2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses. Nat Commun. 2016 Sep 15;7:12752. doi:10.1038/ncomms12752.
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res. 2009 Nov 15;69(22):8678–85. doi:10.1158/0008-5472.CAN-09-2100.
   PubMed Web of Science ®Google Scholar
• Debinski W, Gibo DM, Slagle B, Powers SK, Gillespie GY. Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol. 1999 Sep;15(3):481–86.
   PubMed Web of Science ®Google Scholar
• Papageorgis P, Ozturk S, Lambert AW, Neophytou CM, Tzatsos A, Wong CK, Thiagalingam S, Constantinou AI. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. Breast Cancer Res. 2015 Jul 25;17:98. doi:10.1186/s13058-015-0607-y.
   PubMed Web of Science ®Google Scholar
• Lin C, Liu H, Zhang H, He H, Li H, Shen Z, Qin J, Qin X, Xu J, Sun Y. Interleukin-13 receptor alpha2 is associated with poor prognosis in patients with gastric cancer after gastrectomy. Oncotarget. 2016 Aug 2;7(31):49281–88. doi:10.18632/oncotarget.10297.
   PubMedGoogle Scholar
• Xie M, Wu XJ, Zhang JJ, He CS. IL-13 receptor alpha2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice. Oncotarget. 2015 Oct 20;6(32):32902–13. doi:10.18632/oncotarget.5361.
   PubMedGoogle Scholar
• Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer. 2012 Jul 15;131(2):344–56. doi:10.1002/ijc.26366.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yoshimatsu Y, Tomizawa T, Kunita A, Takayama R, Morikawa T, Komura D, Takahashi K, Oshima T, Sato M et al. Interleukin-13 receptor alpha2 is a novel marker and potential therapeutic target for human melanoma. Sci Rep. 2019 Feb 4;9(1):1281. doi:10.1038/s41598-019-39018-3.
   PubMedGoogle Scholar
• Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM, Lesniak M. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS One. 2013;8(10):e77719. doi:10.1371/journal.pone.0077719.
   PubMed Web of Science ®Google Scholar
• Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget. 2017 Jun 27;8(26):42997–3007. doi:10.18632/oncotarget.17792.
   PubMedGoogle Scholar
• Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, Zhou J, Sahin A, Carter BS, Brem H et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res. 2012 Nov 1;18(21):5949–60. doi:10.1158/1078-0432.CCR-12-0319.
   PubMed Web of Science ®Google Scholar
• Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol. 2014 Oct;16(10):1304–12. doi:10.1093/neuonc/nou045.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Leland P, Joshi BH, Puri RK. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine. 2015 Sep;75(1):79–88. doi:10.1016/j.cyto.2015.05.026.
   PubMed Web of Science ®Google Scholar
• Gupta P, Wentland JA, Leal M, Ma D, Roach R, Esparza A, King L, Spilker ME, Bagi C, Winkelmann CT, et al. Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor alpha2 antibody by fluorescence molecular tomography. Oncotarget. 2017 Aug 22;8(34):57231–45.
   PubMedGoogle Scholar
• Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol. 2011 Jul;38(5):675–81.
   PubMed Web of Science ®Google Scholar
• Berg E, Gill H, Marik J, Ogasawara A, Williams S, van Dongen G, Vugts D, Cherry SR, Tarantal AF, Pet T-B. Highly stable chelators together enable meaningful (89) Zr-AntibodyPET studies up to 30 days after injection. J Nucl Med. 2020 Mar;61(3):453–60. doi:10.2967/jnumed.119.230961.
   PubMed Web of Science ®Google Scholar
• Gupta VR, Root A, Fisher T, Norberg R, David J, Clark T, Cohen J, May C, Giddabasappa A. Molecular imaging reveals biodistribution of P-cadherin LP-DART bispecific and trafficking of adoptively transferred T cells in mouse xenograft model. Oncotarget. 2020 Apr 14;11(15):1344–57. doi:10.18632/oncotarget.27544.
   PubMedGoogle Scholar
• Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012 May;17(9–10):419–24. doi:10.1016/j.drudis.2011.12.020.
   PubMed Web of Science ®Google Scholar
• Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, Brasch RC. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol. 1998 Oct;171(4):941–49. doi:10.2214/ajr.171.4.9762973.
   PubMed Web of Science ®Google Scholar
• Watabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahara M. PET kinetic analysis–compartmental model. Ann Nucl Med. 2006 Nov;20(9):583–88. doi:10.1007/BF02984655.
   PubMed Web of Science ®Google Scholar
• Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. J Nucl Med. 2011 Apr;52(4):625–33. doi:10.2967/jnumed.110.083998.
   PubMed Web of Science ®Google Scholar
• Heskamp S, Raave R, Boerman O, Rijpkema M, Goncalves V, Denat F. (89)Zr-Immuno-Positron emission tomography in oncology: state-of-the-art (89)Zr radiochemistry. Bioconjug Chem. 2017 Sep 20;28(9):2211–23. doi:10.1021/acs.bioconjchem.7b00325.
   PubMed Web of Science ®Google Scholar
• Giddabasappa A, Gupta VR, Norberg R, Gupta P, Spilker ME, Wentland J, Rago B, Eswaraka J, Leal M, Biodistribution SP. Targeting of Anti-5T4 antibody-drug conjugate using fluorescence molecular tomography. Mol Cancer Ther. 2016 Oct;15(10):2530–40. doi:10.1158/1535-7163.MCT-15-1012.
   PubMed Web of Science ®Google Scholar
• Nahrendorf M, Keliher E, Marinelli B, Waterman P, Feruglio PF, Fexon L, Pivovarov M, Swirski FK, Pittet MJ, Vinegoni C et al. Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7910–15. doi:10.1073/pnas.0915163107.
   PubMed Web of Science ®Google Scholar
• Solomon M, Nothdruft RE, Akers W, Edwards WB, Liang K, Xu B, Suddlow GP, Deghani H, Tai YC, Eggebrecht AT, et al. Multimodal fluorescence-mediated tomography and SPECT/CT for small-animal imaging. J Nucl Med. 2013 Apr;54(4):639–46. doi:10.2967/jnumed.112.105742.
   PubMed Web of Science ®Google Scholar
• Ocak M, Gillman AG, Bresee J, Zhang L, Vlad AM, Muller C, Schibli R, Edwards WB, Anderson CJ, Gach HM. Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model. Mol Pharm. 2015 Feb 2;12(2):542–53. doi:10.1021/mp500628g.
   PubMedGoogle Scholar
• Marti-Bonmati L, Sopena R, Bartumeus P, Sopena P. Multimodality imaging techniques. Contrast Media Mol Imaging. 2010 Jul-Aug;5(4):180–89. doi:10.1002/cmmi.393.
   PubMed Web of Science ®Google Scholar
• Cilliers C, Nessler I, Christodolu N, Thurber GM. Tracking antibody distribution with near-infrared fluorescent dyes: impact of dye structure and degree of labeling on plasma clearance. Mol Pharm. 2017 May 1;14(5):1623–33. doi:10.1021/acs.molpharmaceut.6b01091.
   PubMedGoogle Scholar
• Cilliers C, Liao J, Atangcho L, Thurber GM. Residualization rates of near-infrared dyes for the rational design of molecular imaging agents. Mol Imaging Biol. 2015 Dec;17(6):757–62. doi:10.1007/s11307-015-0851-7.
   PubMed Web of Science ®Google Scholar
• Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017 Jan 11;9(372):eaag2611. doi:10.1126/scitranslmed.aag2611.
   PubMed Web of Science ®Google Scholar
• Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 2013 Jun;138(3):452–69. doi:10.1016/j.pharmthera.2013.03.004.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Wesolowski R, Baffa R, Liao KH, Hua SY, Gibson BL, Pirie-Shepherd S, Tolcher AW. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest New Drugs. 2020 Feb;38(1):120–30. doi:10.1007/s10637-019-00754-y.
   PubMed Web of Science ®Google Scholar
• Saka M, Amano T, Kajiwara K, Yoshikawa K, Ideguchi M, Nomura S, Fujisawa H, Kato S, Fujii M, Ueno K, et al. Vaccine therapy with dendritic cells transfected with Il13ra2 mRNA for glioma in mice. J Neurosurg. 2010 Aug;113(2):270–79. doi:10.3171/2009.9.JNS09708.
   PubMed Web of Science ®Google Scholar
• Bartolome RA, Jaen M, Casal JI. An IL13Ralpha2 peptide exhibits therapeutic activity against metastatic colorectal cancer. Br J Cancer. 2018 Oct;119(8):940–49. doi:10.1038/s41416-018-0259-7.
   PubMed Web of Science ®Google Scholar
• Joyce AP, Wang M, Lawrence-Henderson R, Filliettaz C, Leung SS, Xu X, O’Hara DM. One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics. Pharm Res. 2014 Jul;31(7):1823–33. doi:10.1007/s11095-013-1286-y.
   PubMed Web of Science ®Google Scholar